Get the Stockscreener App
0.1752
0.34%
-0.0006
Syros Pharmaceuticals Inc stock is traded at $0.1752, with a volume of 53,363.
It is down -0.34% in the last 24 hours and down -16.17% over the past month.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
See More
Previous Close:
$0.1758
Open:
$0.1801
24h Volume:
53,363
Relative Volume:
0.01
Market Cap:
$4.72M
Revenue:
$9.94M
Net Income/Loss:
$-144.49M
P/E Ratio:
-0.0347
EPS:
-5.05
Net Cash Flow:
$-103.90M
1W Performance:
-5.30%
1M Performance:
-16.17%
6M Performance:
-89.75%
1Y Performance:
-97.51%
1-Day Range:
$0.1724
$0.1801
1-Week Range:
$0.1724
$0.1998
52-Week Range:
$0.16
$7.96
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Name
Syros Pharmaceuticals Inc
Sector
Industry
Phone
617-744-1340
Address
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Compare SYRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.1752 | 4.72M | 9.94M | -144.49M | -103.90M | -5.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.10 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.67 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
647.22 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.35 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.36 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-19 | Resumed | JMP Securities | Mkt Outperform |
| Feb-14-19 | Resumed | Oppenheimer | Outperform |
| Nov-05-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-13-18 | Reiterated | Wedbush | Outperform |
| Oct-31-17 | Resumed | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | ROTH Capital | Neutral |
| Aug-10-17 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
View All
Syros Pharmaceuticals Inc Stock (SYRS) Latest News
What Did We Find About Insider Trading At Syros Pharmaceuticals Inc (NASDAQ: SYRS)? - Stocks Register
StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Syros Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.17, Down -3.99 - The Dwinnex
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Now Carries A 12-Month Price Target Of $5. - Marketing Sentinel
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Investors to Inquire about Securities Investigation - ACCESS Newswire
Syros Pharmaceuticals Inc [NASDAQ: SYRS] Sees Increase in Stock Value - Knox Daily
Check Out Syros Pharmaceuticals Inc (SYRS)’s Trade Data Rather Than the Analysts’ Views - SETE News
Syros Pharmaceuticals Inc (SYRS) Stock Price and Analyst Predictions - The News Heater
H.C. Wainwright Upgrades Syros Pharmaceuticals Inc (SYRS) to a Buy from a Neutral - Knox Daily
Ratio Examination: Syros Pharmaceuticals Inc (SYRS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - MSN
Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33 - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) versus Syros Pharmaceuticals (NASDAQ:SYRS) Financial Analysis - Defense World
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Fell -2280.95%, Predicting What To Expect In The Near Future - Marketing Sentinel
SYRS News Today | Why did Syros Pharmaceuticals stock go down today? - MarketBeat
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by Analysts at StockNews.com - Defense World
Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com - Defense World
Analysts’ Revisions Show Improving Sentiment For Syros Pharmaceuticals Inc (NASDAQ: SYRS) - Stocks Register
Syros Pharmaceuticals (NASDAQ: SYRS) Receives Notice of Listing Non-ComplianceOn January 6, 2025, Syros Pharmaceuticals, Inc. received deficiency letters from the Nasdaq Stock Market, LLC, highlighting certain non-compliance issues with Nasdaq listi - Defense World
Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com
Syros Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com South Africa
StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Brokerages Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33 - Defense World
November's phase III successes; Syros, Cassava tumble on misses - BioWorld Online
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World
Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com India
JMP Securities Downgrades Syros Pharmaceuticals (SYRS) - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - The Eastern Progress Online
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 - Investing.com
Syros Pharmaceuticals (LTS:0LC7) Enterprise Value : $8.13 Mil (As of Jan. 03, 2025) - GuruFocus.com
SYRS (Syros Pharmaceuticals) 9-Day RSI : 26.16 (As of Nov. 24, 2024) - GuruFocus.com
Syros cut to neutral by H.C. Wainwright on failed drug study - MSN
Syros pharmaceuticals chief development officer sells shares for $7,949 - Investing.com India
Syros pharmaceuticals chief medical officer sells shares for $2,382 By Investing.com - Investing.com Australia
Syros Pharmaceuticals chief legal officer sells $10,320 in stock By Investing.com - Investing.com Australia
Syros Pharmaceuticals chief legal officer sells $10,320 in stock - Investing.com India
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 By Investing.com - Investing.com Canada
Syros pharmaceuticals chief medical officer sells shares for $2,382 - Investing.com
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros Pharmaceuticals Inc Stock (SYRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):